Human Genome Sciences, Inc. · Rockville, MD United States (NASDAQ: HGSI)
| 14200 Shady Grove Rd. | Phone: 301-309-8504 |
| Rockville, MD | Fax: 301-309-8512 |
| 20850 | |
| United States | 
Map This Company |
Human Genome Sciences, Inc. Rankings
More Companies in These Related Industries: Pharmaceutical Preparation MfgCompany Description
Human Genome Sciences (HGS) knows that the path to good health starts at the molecular level. Using its expertise in human genetics, the biopharmaceutical discovery and development firm is working on therapies for infectious and autoimmune diseases, cardiovascular disease, and cancer. In 2011 lead candidate Benlysta gained FDA approval to treat systemic lupus. Previously, the company's only product approved for sale was an antibody treatment for inhaled anthrax. Benlysta was developed through a partnership with
Human Genome Sciences, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: HGSI Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 1,100 |
Executives
80 executives listed for Human Genome Sciences, Inc.'s Rockville, MD location.
| Chairman | Argeris Karabelas | |
|---|---|---|
| Executive Director; Executive Director Investor Relations | Claudine Prowse | |
| President, CEO, and Director | H. Thomas Watkins |